The pharmaceutical sector continues to diverge! Northeast Pharmaceutical 6 days 4 boards, Shu Taishen and other bucked the trend

【Pharmaceutical Network Pharmaceutical Stock Market】News on December 20, the pharmaceutical sector continued to diverge, in terms of individual stocks, China Pharmaceutical, which had risen for three consecutive days, touched the intraday limit, and stocks such as Guangshengtang, Hengdi Pharmaceutical, and Jingjing Pharmaceutical fell first, falling by more than 7%; and Northeast Pharmaceutical's price limit to achieve "6 days and 4 boards"; In addition, Shutai Shen, Shanghai Kaibao, etc.
rose sharply against the trend, of which Shu Tai Shen rose nearly 13%
intraday.
Northeast Pharmaceutical, which recently attracted attention due to "2 yuan and 20 tablets of antipyretic drugs", rose again after the opening on December 20, achieving "6 days and 4 boards", as of the close of the day, the stock rose 10.
05%, and the stock price was 8.
54 yuan, a new high
in 6 years.
On the news, Northeast Pharmaceutical disclosed abnormal fluctuations in stock trading announcement, saying that the company's current production and operation are normal, and the business structure has not undergone major changes
.
Recently, the market demand for antipyretic and analgesic drugs has increased, and the company has stepped up the production of acetaminophen tablets, compound aminophenolamine tablets and vitamin C series preparations according to market demand to ensure market supply
.
As of the close of trading on December 20, Shu Taishen rose by nearly 10%, with a quotation of 15.
68 yuan, a turnover of 654 million, and a turnover rate of 9.
13%.

On the news, Shu Taishen recently announced that GST-HG171, a first-class innovative drug of Fujian Guangsheng Zhonglin Biotechnology Co.
, Ltd.
, a subsidiary of the company's innovative drug holding company, recently obtained the review approval of the ethics committee of the First Affiliated Hospital of Guangzhou Medical University and the Third People's Hospital of Shenzhen on the initiation of phase II/III clinical trials, marking that the key registered clinical research of the seamless design of phase II/III of the company's GST-HG171 project has been fully and substantially launched
。 At the same time, the clinical study (IIT study) initiated by the investigator to evaluate the efficacy and safety of the preliminary drug has successfully completed the enrollment and administration of all patients, and the report
is yet to be summarized.
The company said it will be fully committed to efficiently advancing key registered clinical studies
.
According to the data, Shutaishen is an enterprise engaged in the research and development, production and sales of biological products and some chemicals, the company's main products are independent research and development of national class I new drugs - injectable murine nerve growth factor "threonin" and colon cleansing and constipation drugs with both colon cleansing and constipation indications - polyethylene glycol electrolyte powder "Shutaiqing", in addition to the production of aspirin enteric-coated tablets, glicide tablets and nabumetone capsules and other three drugs
.
At the same time, there are still several national Class I new drugs and new drugs with independent intellectual property rights in different stages
of research and development or application, from laboratory to clinical trials.
In the next three to five years, the company will have a number of new products with independent intellectual property rights put into the market
.
Shanghai Kaibao closed at 11.
69 yuan on the 20th, an increase of 1.
12%, with a turnover of 1.
905 billion yuan and a turnover rate of 17.
30%.

On the news, Shanghai Kaibao said on the investor interactive platform on December 19 that the company's product phlegm hot clear capsules are national varieties, and the medical insurance payment standard is 4.
09 yuan / (0.
4g / capsule).

At present, the company makes every effort to ensure product production and market supply, and the subsequent company will be determined
according to the enterprise development and business plan.
It is understood that previously, phlegm heat clearing capsules have been included in the home medicine intervention guidelines
.
On December 20, the company also announced that it recently received an invention patent certificate issued by the State Intellectual Property Office, which is a method
for determining the content of four related components of bear bile powder in sputum heat clearing injection.
The invention patent discloses a method
for determining the content of four related components of bear bile powder in sputum heat clear injection.
The acquisition of the above-mentioned invention patents will help the company to give full play to the advantages of independent intellectual property rights, strengthen the protection of independent intellectual property rights and further improve the company's intellectual property protection system, enhance the company's core competitiveness, and will not have a significant impact
on the current production and operation.
China Pharmaceutical, which had previously walked out of the 3-day limit of rise, closed down nearly 10% on the 20th, with a quotation of 20.
10 yuan, a turnover of 4.
235 billion yuan, and a turnover rate of 13.
66%.

In this regard, China National Pharmaceutical also issued a risk warning on the evening of the 20th, saying that the company's recent stock price increase has exceeded the impact of related matters on the company's performance, and there is irrational investment, please pay attention to investment risks, rational decision-making, prudent investment
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.